INTRODUCTION {#s1}
============

Immunotherapy has become one of the best strategies to treat several tumors in recent years. Immune checkpoint blockade (ICB) through anti-Programmed Cell Death-1 (anti-PD-1), anti-Programmed Cell Death-Ligand 1 (anti-PD-L1) and anti-Cytotoxic T Lymphocyte-associated Antigen-4 (anti-CTLA-4) monoclonal antibodies (mAbs) represents a way of modulating the immune system, with remarkable outcomes.

Unfortunately, a significant number of patients do not benefit from ICB, and up to 40% of patients treated with ICB obtain a status of progressive disease (PD) as best response with these anti-PD-1/PD-L1/CTLA-4 mAbs \[[@R1]--[@R6]\].

Different molecular mechanisms of resistance to immunotherapy are being elucidated, from which some actionable strategies to prevent or treat them could be derived. Most contemporary approaches focus on combination strategies in an effort to overcome resistance to monotherapy \[[@R7]\]. Combined therapy with blocking antibodies against key immune checkpoints, mainly CTLA-4 and PD-1 (but also anti-VISTA, anti-LAG-3 or anti-TIM-3 mAbs), constitutes an example of potential enhanced efficacy. For example, the combination nivolumab plus ipilimumab results in higher response rates compared to nivolumab or ipilimumab as monotherapy, and improved overall survival in patients with metastatic melanoma \[[@R8], [@R9]\]. Traditional chemotherapy (CTx) is also being combined with ICB strategies. The safety profile is probably the most common concern in treating patients with these combinations. ICB monotherapy has shown a better toxicity profile compared to CTx, with lower all-grade and grade 3/4 adverse events. Nevertheless, it is associated with a small but significant increase in the risk of selected all-grade immune-related adverse events and high-grade gastrointestinal and liver toxicities \[[@R10]\]. Overall, immune checkpoint inhibitors present a manageable safety profile, obtaining good outcomes by the implementation of dose interruptions and use of steroids when required. Combination treatments appear to have a less favorable safety profile compared with the monotherapy strategy. Combination treatment with CTx plus ICB could be associated with more high-grade adverse events and higher treatment discontinuation rates, similar to the pattern observed with ipilimumab plus nivolumab \[[@R8]\].

While combination therapies have the potential to achieve significant improvements in efficacy, their effectiveness has been derived from empirically chosen combinations, which can sometimes lead to higher toxicity as well as treatment discontinuations that may result in worse outcomes.

The safety profile of CTx plus ICB is not completely understood compared to monotherapy. We therefore performed a meta-analysis of published randomized clinical trials (RCT) in order to analyze the main safety endpoints (treatment-related adverse events, deaths and discontinuations) obtained with the combination of CTx plus ICB (anti-PD-1/PD-L1/CTLA-4 mAbs) compared to each treatment as monotherapy (CTx or ICB).

PATIENTS AND METHODS {#s2}
====================

Literature search and inclusion criteria {#s2_1}
----------------------------------------

We identified all RCTs that compared combined treatments (CTx plus ICB, which comprises the concurrent use of CTx along with ICB) with CTx agents or currently approved immune checkpoint inhibitors (anti-PD-1, anti-PD-L1 or anti-CTLA-4 mAbs) as monotherapy. The immune checkpoint inhibitors included in this study were: nivolumab (Opdivo^®^), pembrolizumab (Keytruda^®^), atezolizumab (Tecentric^®^), durvalumab (Imfinzi^®^), avelumab (Bavencio^®^), ipilimumab (Yervoy^®^) and tremelimumab. An independent search of published studies from January 1, 2010 to July 1, 2018 in MEDLINE and EMBASE was performed. The following search terms were used: ("nivolumab" OR "pembrolizumab" OR "atezolizumab" OR "durvalumab" OR "avelumab" OR "ipilimumab" OR "tremelimumab") AND ("trial" OR "randomized"). A parallel search entering the names of the agents and filtering the results by clinical trial type was conducted. The review was restricted to RCTs in human subjects published in English. We reviewed each publication, and only the most recent or complete report of RCTs was included when duplicate publications were identified. On July 1, 2018, the online updated manufacturers' package inserts for nivolumab, pembrolizumab, atezolizumab, durvalumab, avelumab, ipilimumab and tremelimumab were also reviewed to identify relevant information not previously reported in published clinical trials. Trials involving combinations of ICB with agents other than CTx (mainly between two different immune checkpoint inhibitors) were excluded in order to reduce the potential heterogeneity among the results. Selected safety endpoints included: rates of adverse events (AEs; both all-grade and grade 3/4 adverse events), treatment-related deaths (deaths), and treatment discontinuations (discontinuations). Trials that met the following criteria were included in the meta-analysis: randomized phase I, II and III trials, prospective clinical trials in patients with cancer, and trials with at least one of the previous safety endpoints mentioned above available. Only studies with solid tumors were included. Two reviewers (A. C-G. and G.d.V.) independently evaluated studies for eligibility.

Data extraction and clinical endpoints {#s2_2}
--------------------------------------

Data were extracted as already outlined, after a preliminary screen by two investigators (A. C-G. and G. d. V.) according to Quality of Reporting of Meta-Analyses (QUORUM) guidelines. Variables collected and included were: first author's surname, year of publication, National Clinical Trials (NCT) registry number, study phase, type of underlying malignancy, number of previous treatments received, selection of population by PD-L1 expression on tumor cells (yes/no), number of enrolled subjects, number of patients available for safety analysis, criteria used for grading adverse events, blinding (yes/no), treatment arms, number of patients per treatment arm, name of the immune checkpoint inhibitor (nivolumab, pembrolizumab, atezolizumab, durvalumab, avelumab, ipilimumab, tremelimumab), and median age. The safety endpoints selected for the analysis (% all-grade AEs, grade 3/4 AEs, deaths and discontinuations) were also obtained per treatment group to compare outcomes with the combination versus monotherapy.

Statistical analysis {#s2_3}
--------------------

All statistical analyses were performed using meta package \[[@R11], [@R12]\]. For binary outcomes, all-grade AEs/grade 3/4 AEs/deaths/discontinuations risk ratios with confidence intervals (CIs) were used as the measure of safety of the CTx plus ICB arm versus the monotherapy (either CTx or ICB) arm (control arm). Statistical heterogeneity among trials included in the meta- analysis was assessed using Higgins´s I^2^ statistics, which estimates the percentage of total variation across studies due to heterogeneity rather than chance \[[@R13]\], and Cochran´s Q test with under the null hypothesis of no heterogeneity. We pooled studies using random and fixed-effects models depending on the heterogeneity of the studies included. When substantial heterogeneity was not observed, the summary estimate calculated on the basis of the fixed-effects model was reported using the Mantel-Haenszel method; otherwise, the random effects model was reported using the DerSimonian and Laird method that considers both within-study and between-study variations \[[@R14]\]. Subgroup analyses were conducted by control group (CTx or ICB as monotherapy) and by class of immune checkpoint inhibitor evaluated (in the monotherapy and/or combination treatment arms: anti-CTLA-4 mAb trials or anti-PD-1/PD-L1 mAb trials). As in the overall analysis, the purpose of these subgroup analyses was to compare monotherapy versus combination treatment in different subsets of populations. In addition, publication bias was evaluated using funnel plots (i.e. plots of study results against precision).

RESULTS {#s3}
=======

Study selection {#s3_1}
---------------

Studies selected are shown in the flow chart ([Figure 1](#F1){ref-type="fig"}). A total of 1948 studies were reviewed through our screening process for RCTs. Exclusions were: (i) letters, editorials, reviews and retrospective studies (1526 studies); (ii) expanded-access studies with no control arm and early phase I/II or non-RCTs (289 studies); and (iii) studies with only efficacy results or no adequate control arm (123 studies). Ten trials met the criteria for inclusion in the meta-analysis (randomized phase I/II/III trials with CTx plus ICB compared to CTx/ICB in monotherapy as the control arm). As explained above, studies were carried out in patients with different metastatic solid tumors.

![Flow diagram of the systematic review.](oncotarget-10-3294-g001){#F1}

The baseline characteristics of each trial are presented in [Table 1](#T1){ref-type="table"} \[[@R15]--[@R24]\]. Five trials were performed in patients with non-small cell lung cancer, two in patients with small cell lung cancer and three in melanoma. All were performed in the first-line setting. All studies had two treatment arms except three, which had three arms \[[@R16], [@R17], [@R22]\]. The IMpower150 study has three treatment arms, but results for only two of them have been published to date (results for atezolizumab combined with paclitaxel and carboplatin are pending) \[[@R24]\]. In two studies, ICB monotherapy was the control arm (ipilimumab) \[[@R20], [@R22]\]; the remaining studies used CTx as monotherapy (usually combined cytotoxic agents). Seven studies included anti-CTLA-4 mAbs (ipilimumab) and three studies included anti-PD-1/PD-L1 mAbs (pembrolizumab and atezolizumab). None of the studies selected populations according to PD-L1 expression on tumor cells or immune cells. Some of the studies used PD-L1 expression criteria as a stratification factor but no independent results have been published. A total of 4598 patients were available for the meta-analysis, 4379 of whom had safety data available: 2026 patients were assigned to monotherapy (1967 to combined chemotherapy regimens, 59 to ipilimumab), and 2353 were assigned to CTx plus ICB arms (1496 including ipilimumab, 464 including pembrolizumab, and 393 including atezolizumab). Four of these studies did not specify a relationship between at least one selected safety endpoint and the administered treatment (no treatment-related data available) \[[@R16], [@R21]--[@R23]\]. Safety was a secondary endpoint in all of the studies. Common Terminology Criteria for Adverse Events (CTCAE) was the criteria used to assess and grade adverse events (mainly versions 3.0 and 4.0). All RCTs were sponsored by pharmaceutical companies.

###### List of clinical trials included in the meta-analysis

                                                                                             Reference                      Phase   Histology                       Masking        No. patients (safety data)   Treatment arms
  ------------------------------------------------------------------------------------------ ------------------------------ ------- ------------------------------- -------------- ---------------------------- ----------------------------------------
  1                                                                                          Reck M, *et al.* (2016)        3       Small cell lung cancer (SCLC)   Double-blind   954                          Platinum + Etoposide + Placebo
  Platinum + Etoposide + Ipilimumab                                                                                                                                                                             
  2                                                                                          Reck M, *et al.* (2012)        2       SCLC                            Double-blind   128                          Paclitaxel + Carboplatin + Placebo
  (Paclitaxel + Carboplatin + Placebo) followed by (Paclitaxel + Carboplatin + Ipilimumab)                                                                                                                      
  (Paclitaxel + Carboplatin + Ipilimumab) followed by (Paclitaxel + Carboplatin + Placebo)                                                                                                                      
  3                                                                                          Lynch TJ, *et al.* (2012)      2       Non-small cell lung cancer      Double-blind   203                          Paclitaxel + Carboplatin + Placebo
  (Paclitaxel + Carboplatin + Placebo) followed by (Paclitaxel + Carboplatin + Ipilimumab)                                                                                                                      
  (Paclitaxel + Carboplatin + Ipilimumab) followed by (Paclitaxel + Carboplatin + Placebo)                                                                                                                      
  4                                                                                          Govindan R, *et al.* (2017)    3       NSCLC (Squamous-Sq-)            Double-blind   948                          Paclitaxel + Carboplatin + Placebo
  (Paclitaxel + Carboplatin + Placebo) followed by (Paclitaxel + Carboplatin + Ipilimumab)                                                                                                                      
  5                                                                                          Langer CJ, *et al.* (2016)     2       NSCLC (Non-Sq)                  Open-label     121                          Carboplatin + Pemetrexed
  Carboplatin + Pemetrexed + Pembrolizumab                                                                                                                                                                      
  6                                                                                          Hersh EM, *et al*. (2011)      2       Melanoma                        Open-label     74                           Ipilimumab
  Ipilimumab + Dacarbazine                                                                                                                                                                                      
  7                                                                                          Robert C, *et al.* (2011)      3       Melanoma                        Double-blind   498                          Placebo + Dacarbazine
  Ipilimumab + Dacarbazine                                                                                                                                                                                      
  8                                                                                          Weber J, *et al.* (2013)       1       Melanoma                        Open-label     59                           Ipilimumab
  Ipilimumab + Dacarbazine                                                                                                                                                                                      
  Ipilimumab + Paclitaxel + Carboplatin                                                                                                                                                                         
  9                                                                                          Gandhi L, *et al.* (2018)      3       NSCLC (Non-Sq)                  Double-blind   607                          Platinum + Pemetrexed + Placebo
  Platinum + Pemetrexed + Pembrolizumab                                                                                                                                                                         
  10                                                                                         Socinski MA, *et al.* (2018)   3       NSCLC (Non-Sq)                  Open-label     787                          Bevacizumab + Paclitaxel + Carboplatin
  Atezolizumab + Bevacizumab + Paclitaxel + Carboplatin                                                                                                                                                         
  Atezolizumab + Paclitaxel + Carboplatin (results not reported)                                                                                                                                                

Incidence and relative risk of all-grade AEs and grade 3/4 AEs {#s3_2}
--------------------------------------------------------------

In patients receiving CTx plus ICB, all-grade AEs were confirmed in 2142/2353 patients (91.03%) compared to 1751/2026 (86.43%) in those patients on monotherapy \[Relative risk (RR) 1.04; 95% CI 1.00-1.08, *p* = 0.048 ([Figure 2A](#F2){ref-type="fig"})\].

![Forest plot diagrams: Relative risk (RR) with 95% confidence interval (CI) of safety endpoints between combination treatment and monotherapy.\
(**A**) All-grade AEs. (**B**) Grade 3/4 AEs. (**C**) Deaths. (**D**) Discontinuations.](oncotarget-10-3294-g002){#F2}

Grade 3/4 AEs were reported in 1263/2353 (53.68%) patients receiving CTx plus ICB, compared to 839/2026 (41.41%) in patients treated with monotherapy. An increased risk of grade 3/4 AEs was shown in patients treated with CTx plus ICB: RR 1.32; 95% CI 1.12--1.55, *p* = 0.0008 ([Figure 2B](#F2){ref-type="fig"}). Two studies included did not specify whether the AEs were related or not to the study treatments \[[@R21], [@R23]\].

Incidence and relative risk of deaths {#s3_3}
-------------------------------------

Deaths were notified in 54/2353 (2.30%) patients treated with CTx plus ICB, while this event was observed in 29/2026 (1.43%) of patients receiving treatment as monotherapy. No differences were found between groups: RR 1.30; 95% CI 0.84-2.00, *p* = 0.24 ([Figure 2C](#F2){ref-type="fig"}). One study did not specify the relationship between deaths and study treatments \[[@R23]\].

Incidence and relative risk of discontinuations {#s3_4}
-----------------------------------------------

Treatment discontinuations were reported in 530/2353 (22.52%) patients who received CTx plus ICB, and in 188/2026 (9.28%) patients managed with monotherapy. CTx plus ICB was associated with higher rate of discontinuations compared to monotherapy: RR 2.31; 95% CI 1.28-4.16, *p* = 0.006 ([Figure 2D](#F2){ref-type="fig"}).

Subgroup analyses ([Table 2](#T2){ref-type="table"}) {#s3_5}
----------------------------------------------------

According to the monotherapy control arm (CTx or ICB), results were similar to the overall analysis, with no significant differences observed between these groups in any of the safety endpoints compared with CTx plus ICB.

###### Subgroup analysis according to monotherapy control arm (chemotherapy or immunotherapy) and class of immune checkpoint inhibitor (anti-CTLA-4 mAb or anti-PD-1/PD-L1 mAb)

  Subgroup analysis by control arm in monotherapy   Chemotherapy in monotherapy   Immunotherapy in monotherapy   *p*-value for difference
  ------------------------------------------------- ----------------------------- ------------------------------ --------------------------
  All grade-AEs                                     RR 1.03; 95% CI 0.99--1.07    RR 1.13; 95% CI 1.00--1.28     0.15
  Grade 3/4 AEs                                     RR 1.30; 95% CI 1.09--1.54    RR 1.54; 95% CI 1.00--2.36     0.48
  Deaths                                            RR 1.32; 95% CI 0.85--2.05    RR 0.87; 95% CI 0.10--7.89     0.72
  Discontinuations                                  RR 2.40; 95% CI 1.24--4.65    RR 1.51; 95% CI 0.67--3.42     0.39

  Subgroup analysis by class of immune checkpoint inhibitor   anti-CTLA-4 mAb              anti-PD-1/PD-L1 mAb          *p*-value for difference
  ----------------------------------------------------------- ---------------------------- ---------------------------- --------------------------
  All grade-AEs                                               RR 1.06; 95% CI 1.03--1.10   RR 1.00; 95% CI 0.99--1.02   0.0004
  Grade 3/4 AEs                                               RR 1.42; 95% CI 1.14--1.79   RR 1.11; 95% CI 0.96--1.28   0.07
  Deaths                                                      RR 1.92; 95% CI 0.83--4.45   RR 1.11; 95% CI 0.67--1.86   0.28
  Discontinuations                                            RR 3.22; 95% CI 1.66--6.23   RR 1.34; 95% CI 1.07--1.67   0.01

Based on the type of immune checkpoint inhibitor combined with CTx, the combination of CTx with an anti-CTLA-4 mAb was associated with a greater increase in all-grade AEs compared to monotherapy (RR 1.06; 95% CI 1.03--1.10). However, there were no differences when the combination with CTx was an anti-PD-1/PD-L1 mAb (RR 1.00; 95% CI 0.99--1.02). A tendency towards a higher number of grade 3/4 AEs was observed with the use of anti-CTLA4 mAb in combination compared to anti-PD-1/PD-L1 mAb, but this was not statistically significant (*p* = 0.07). Mortality was similar between the two types of ICB agents. The anti-CTLA4 combination presented more treatment discontinuations compared to anti-PD-1/PD-L1 mAb combinations with CTx (RR 3.22; 95% CI 1.66-6.23 versus RR 1.34; 95% CI 1.07--1.67, respectively).

DISCUSSION {#s4}
==========

For many years now, oncologists have combined different drugs to achieve better outcomes. Most combination strategies have emerged empirically without considering overlapping safety profiles. Whether combination compared to sequential treatment is a better strategy overall is usually a matter for debate.

The use of ICB as monotherapy has generally shown a good safety profile without potential overlapping toxicities with CTx, and as such it seems reasonable to combine these two therapeutic strategies.

This meta-analysis has shown that the combination of ICB with CTx is associated with an increase in grade 3/4 AEs and higher rates of treatment discontinuation when compared to monotherapy in different solid tumors. Importantly, fatal adverse events (deaths) do not seem to be increased with the combination of CTx and ICB.

Subgroup analysis for the control group (CTx or ICB as monotherapy) showed no differences, confirming a worse safety profile with the use of combined treatment. This subanalysis could be limited by the small number of events in the ICB monotherapy group.

We should take into account that up to 70% of the trials in this analysis included ipilimumab. CTx plus ICB with CTLA-4 mAbs (ipilimumab) showed a significant increase in all-grade AEs and discontinuations compared to CTx and anti-PD-1/PD-L1 mAbs, probably as a consequence of the poorer safety profile observed with anti-CTLA-4 mAbs in monotherapy compared to anti-PD-1/PD-L1 \[[@R10]\].

Despite the worse safety profile and higher treatment discontinuation rates for the combination strategy, its efficacy has been proven. At this point, the issue is to predict which patients might really benefit from combination therapy and which might have poor tolerance. One example would be to establish if PD-L1 expression levels could select patients in some indications for monotherapy, avoiding unnecessary toxicities.

CTx plus ICB has been extensively tested in several advanced tumors, where the main goal for patients is to increase overall survival as well as to maintain quality of life. It is therefore extremely important to consider the toxicity implications of combined CTx plus ICB, and to carefully balance the risk and benefits of the new strategies.

The impact of increased treatment discontinuations on outcomes is not yet completely understood. A pooled analysis of patients with advanced melanoma who received nivolumab combined with ipilimumab concluded that efficacy outcomes were similar between patients who discontinued nivolumab plus ipilimumab treatment because of AEs during the induction phase and those who did not discontinue because of AEs. Thus, even after discontinuation, some patients may continue to benefit \[[@R25]\]. In addition, sequential strategies also need to be properly compared to combination therapies, to establish the actual relative benefit with these two modalities.

There are still many questions to be answered regarding the optimal dose, regimen or duration of therapy for many CTx plus ICB combinations. The development of better ways to manage toxicities also needs to be addressed, to avoid treatment discontinuations and try to maintain the proposed treatment regimen. These questions can only be explored through prospective clinical trials and extensive collaborative research.

This meta-analysis has several limitations. It includes a heterogeneous population (different tumor types or population enriched by PD-L1 expression in some studies, different combination treatments). Although rather similar, there were minor variations in the safety criteria used to evaluate and grade the adverse events (mainly CTCAE criteria versions 3.0 and 4.0). In addition, we were unable to retrieve patient-level data, although some studies have suggested trial-level and patient-level meta-analyses may reach comparable outcomes \[[@R26]\]. Finally, in this study, we did not evaluate the effect of maintenance strategies on the toxicity profile. In conclusion, in this meta-analysis, CTx plus ICB is associated with an increase in grade 3/4 AEs and treatment discontinuations compared to monotherapy (both CTx and ICB). Treatment-related deaths were not increased in the CTx plus ICB group. Many clinical trials are combining multiple strategies to develop the most effective combination in immuno-oncology. The identification of biomarkers that predict efficacy as well as the risks of adverse effects is essential to improve the benefit-risk balance of treatment for our patients.
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